000279481 001__ 279481
000279481 005__ 20250710100950.0
000279481 037__ $$aDZNE-2025-00808
000279481 1001_ $$0P:(DE-2719)9001534$$aMuqaku, Besnik$$b0$$udzne
000279481 245__ $$aDataset: Peptidomic analysis of CSF reveals new biomarker candidates for amyotrophic lateral sclerosis
000279481 260__ $$bPRoteomics IDEntifications Database$$c2025
000279481 3367_ $$2BibTeX$$aMISC
000279481 3367_ $$0PUB:(DE-HGF)32$$2PUB:(DE-HGF)$$aDataset$$bdataset$$mdataset$$s1752048358_17545
000279481 3367_ $$026$$2EndNote$$aChart or Table
000279481 3367_ $$2DataCite$$aDataset
000279481 3367_ $$2ORCID$$aDATA_SET
000279481 3367_ $$2DINI$$aResearchData
000279481 520__ $$aAmyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease and novel biomarkers are needed. We applied mass-spectrometry-based peptidomic analysis in cerebrospinal fluid (CSF) samples of ALS and non-neurodegenerative control patients (Con) from a discovery (n=48) and validation (n=109) cohort for biomarker discovery. We identified 33605 peptides in CSF samples from the discovery cohort. Systematic selection for the best candidates revealed a targeted method with eight peptides derived from seven proteins. In the validation cohort, NFL, MAP1B, MYL1, APOC1 peptides were up-regulated and peptides from CADM3, SCG1 and PENK down-regulated in ALS compared to Con. Combination of all peptides in a logistic regression model led to an area under the curve value of 98% for the discrimination of ALS from controls. Data of the NFL peptide strongly correlated with an established NFL immunoassay (Ella, r=0.97). The peptide biomarker candidates are derived from proteins with different function and their determination with our method provides the opportunity for simultaneous investigation of key processes in ALS and other neurodegenerative diseases.
000279481 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000279481 7001_ $$0P:(DE-2719)9001560$$aOeckl, Patrick$$b1$$udzne
000279481 8564_ $$uhttps://wwwdev.ebi.ac.uk/pride/archive/projects/PXD062419
000279481 909CO $$ooai:pub.dzne.de:279481$$pVDB
000279481 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001534$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000279481 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001560$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000279481 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000279481 9141_ $$y2025
000279481 9201_ $$0I:(DE-2719)5000073$$kAG Öckl$$lTranslational Mass Spectrometry and Biomarker Research$$x0
000279481 980__ $$adataset
000279481 980__ $$aVDB
000279481 980__ $$aI:(DE-2719)5000073
000279481 980__ $$aUNRESTRICTED